Background: The olfactory ensheathing cells (OECs) migrate from the peripheral nervous system to the central nervous system (CNS), a critical process for the development of the olfactory system and axonal extension after injury in neural regeneration. Because of their ability to migrate to the injury site and anti-inflammatory properties, OECs were tested against different neurological pathologies, but were never studied in the context of cancer. Here, we evaluated OEC tropism to gliomas and their potential as a "Trojan horse" to deliver therapeutic transgenes through the nasal pathway, their natural route to CNS. Methods: OECs were purified from the mouse olfactory bulb and engineered to express a fusion protein between cytosine deaminase and uracil phosphoribosyltransferase (CU), which convert the prodrug 5-fluorocytosine (5-FC) into cytotoxic metabolite 5-fluorouracil, leading to a bystander killing of tumor cells. These cells were injected into the nasal cavity of mice bearing glioblastoma tumors and OEC-mediated gene therapy was monitored by bioluminescence imaging and confirmed with survival and ex vivo histological analysis. All statistical tests were two-sided. Results: OECs migrated from the nasal pathway to the primary glioma site, tracked infiltrative glioma stemlike cells, and delivered therapeutic transgene, leading to a slower tumor growth and increased mice survival. At day 28, bioluminescence imaging revealed that mice treated with a single injection of OEC-expressing CU and 5-FC had tumor-associated photons (mean [SD]) of 1.08E þ 08 [9.7E þ 07] vs 4.1E þ 08 [2.3E þ 08] for control group (P < .001), with a median survival of 41 days vs 34 days, respectively (ratio ¼ 0.8293, 95% confidence interval ¼ 0.4323 to 1.226, P < .001) (n ¼ 9 mice per group). Conclusions: We show for the first time that autologous transplantation of OECs can target and deliver therapeutic transgenes to brain tumors upon intranasal delivery, the natural route of OECs to the CNS, which could be extended to other types of cancer.
critical process for the development and maintenance of the olfactory system. During neural regeneration, OECs migrate into the injury site and enhance the axon growth because of their permissive environment (5) . Recently, OECs were shown to have tropism to astrocytes dissociated from GBM tissue in culture (6) . Owing to their strong ability to interact with astrocytes, as well as their immunomodulatory and phagocytic properties, accumulating evidence has led to investigations of the therapeutic potential of OECs in animal models as well as in the clinic for different pathologies, including chronic spinal cord injury and amyotrophic lateral sclerosis (7) (8) (9) (10) ; but OECs were never studied in the context of cancer in vivo. Here, we evaluated the potential of OECs as a Trojan horse to deliver therapeutic transgene to brain tumors through the nasal pathway, their natural route to CNS.
Materials and Methods

Cell Culture of Olfactory Ensheathing Cells
Olfactory ensheathing cells were purified from the olfactory bulbs of C57BL/6 male adult mice following our and others' previously described protocol (11) (12) (13) (14) (15) . Briefly, the mice were killed by isoflurane. The olfactory bulbs were dissected and sliced using a Tissue Chopper (Mickle Laboratory, Gomshall UK) in cold Hank's solution (HBSS, Thermo Fisher Scientific, Waltham, USA). The tissue was dissociated with a TrypLE (Thermo Fisher Scientific) reagent and quenched with Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12; Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS). Cells were then centrifuged at 350Âg for 5 min, the supernatant was discarded, and the cell pellet was resuspended in complete DMEM/F-12 supplemented with 10% FBS and 100 U/mL penicillin-streptomycin (Thermo Fisher Scientific), plated onto an uncoated 60-mm dish, and incubated at 37 C in CO 2 incubator for 18 hours in preparation for fibroblast removal. Next, floating cells in cell suspension were transferred to a second uncoated dish for astrocyte removal, and incubated using the same conditions for 36 hours. Finally, OECs in the cell suspension were adhered onto a precoated laminin (40 lg/mL, Life Technologies) 60-mm cell dish in DMEM/F-12 complete medium. OECs were maintained in 5% CO 2 at 37 C, and the medium was refreshed every three days. Once confluency was reached, OECs were detached using TrypLE and used in the proposed experiments. OECs were then transduced with a lentivirus vector carrying an expression cassette for the naturally secreted Gaussia luciferase (Gluc) and green fluorescent protein (GFP) separated by an internal ribosomal site (IRES), under the control of cytomegalovirus promoter at a multiplicity of infection of 10 transducing units per cell by adding the virus directly to the cell culture (16) . Similarly, OECs were engineered to express a fusion between yeast cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT; CU) under the control of cytomegalovirus (CMV) promoter using a previously described lentivirus construct (17) . OECs expressing CU are referred to as OCU.
Detailed methods for in vitro luciferase cell proliferation/viability analysis, OEC migration assay, apoptosis detection in cocultured cells, bioluminescence imaging, and immunofluorescence experiments are in the Supplementary Methods (available online).
Patient-Derived GBM Stemlike Cells and Cell Lines
MGG6, MGG8, and MGG23 primary glioblastoma stemlike cells (GSCs) were derived from surgical specimens obtained from glioblastoma patients undergoing treatment at the Massachusetts General Hospital (Boston, MA), in accordance with the appropriate institutional review board approval, and have been previously characterized (17, 18) . More details can be found in the Supplementary Methods (available online). GSCs were engineered by a lentivirus vector to express firefly luciferase (Fluc) and mCherry fluorescent protein (mCherry) separated by an IRES, under control of CMV promoter (Fluc-mCherry).
Mouse Studies
All mouse studies were performed in accordance with the Massachusetts General Hospital Subcommittee on Research Animal Care following guidelines set by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Athymic female mice, 8-10 weeks old, were anesthetized with 3% isoflurane under oxygen and stereotactically implanted with 50 000 GBM cells or GSCs (as small spheres) expressing Fluc-mCherry in 2 lL phosphate-buffered saline (PBS) using a 30-gauge Hamilton syringe and the following coordinates: 2.5 mm lateral, 0.5 mm anterior to bregma, and 2.5 mm depth from the skull surface. One week (for therapeutic studies; n ¼ 9 per group) or three weeks (for tropism analysis, n ¼ 3 per experiment) after tumor implantation, mice received 10 5 OEC-GFP (in 10 lL PBS) via intranasal administration by carefully dropping the cells onto their nostrils, allowing cells to be snorted in drop by drop. One week post-OEC injection, mice were treated with a daily intraperitoneal injection of 5-FC (500 mg/kg) for 7 days. Tumor volume was monitored over time by bioluminescence imaging as detailed in the Supplementary Methods (available online).
Statistical Analysis
GraphPad Prism v6.01 (GraphPad Software, Inc, LaJolla, CA) was used for statistical analysis of all data. Data were expressed as mean (SD). An unpaired two-tailed t test was used for the comparison of two samples. A P value less than .05 was considered statistically significant. One-way (for in-culture work) or twoway (for in vivo work) analysis of variance (ANOVA) followed by the Bonferroni multiple comparison post hoc test was performed to compare differences between groups. All of the mice included in the survival curve were followed to their natural death, and survival was analyzed using Kaplan-Meier curves and log-rank (Mantel-Cox) tests. All statistical tests were twosided.
Results
Isolation and Characterization of OEC Cultures
We purified the olfactory ensheathing cells from the olfactory bulbs of C57BL/6 male adult mice following previously established protocol (11) (12) (13) (14) (15) (summarized in Figure 1A ). Costaining of OECs for 2 0 ,3 0 cyclic nucleotide 3 0 -phosphodiesterase, smooth muscle a-actin, glial fibrillary acidic protein, and calciumbinding protein b, specific markers for OEC (13) , revealed that our cultures displayed neither unlabeled cells nor cells labeled with only one marker, confirming that our method is highly effective for OEC purification ( Figure 1B ).
OEC Tropism to Brain Tumors via the Nasal Pathway
We first evaluated whether OECs can travel their natural route from the olfactory bulb to CNS and target brain tumors. MGG8 patient-derived GSC neurospheres (10 To understand the potential mechanism responsible for this tropism, we explored two major cytokines, the tumor necrosis factor alpha (TNFa) and interleukin 6 (IL-6), previously shown to mediate neural or mesenchymal stem cell tropism to tumors/gliomas (18, 19) . Indeed, knocking down (using short hairpin RNA [shRNA]) either of these cytokines in GSCs and the U87 GBM line inhibited OEC migration to their conditioned medium ( These results indicate the potential role of these two secreted inflammatory molecules in OEC tropism to glioblastomas.
OEC as a Delivery Vehicle of Therapeutics to Glioma Cells and Stemlike Cells
We evaluated OECs as a vehicle to deliver therapeutic transgenes to brain tumors. We first engineered OECs to express a fusion protein between CD and UPRT under the control of cytomegalovirus promoter (OCU), as a proof-of-concept transgene. The CD converts, on the tumor site, the prodrug 5-FC into the cytotoxic agent 5-fluorouracyl (5-FU), which is further converted to its metabolites 5-fluorodeoxyuridine-5 0 -monophosphate and 5-fluorouridine-5 0 -triphosphate intracellularly. These active metabolites are then incorporated into DNA and RNA leading to the inhibition of nucleotide synthesis and cell death. The advantage of this strategy is that the generated 5-FU can be transferred to neighboring nontransduced cells via gap junctions and other mechanisms, leading to a bystander killing of tumor cells. In addition, we chose CU fusion as the transgene because UPRT has been shown to have a synergistic antitumor effect with CD where the 5-FU generated through CD (upon addition of prodrug 5-FC) is further metabolized into 5-fluorodeoxyuridine-5 0 -monophosphate by UPRT (20) (21) (22) . Also, CD has been recently evaluated in the first neural stem cell-based gene therapy in humans against malignant gliomas (23) .
To assess the potential use of OEC for glioma gene therapy, we used a dual luciferase reporter system to monitor cell viability in both OEC and GSC/GBM cells, simultaneously in the same well (24) . OCU or OEC (not expressing transgene as a control) were engineered to express the Gluc (coelenterazine as substrate), which will report for OEC viability. GSCs/GBM cells (three different cultures), on the other hand, were engineered to express Fluc (D-luciferin as substrate). We either cultured each cell type separately or cocultured OECs and GSCs/GBM cells together in the presence or absence of 500 mM 5-FC or 500 mM 5-FU (a positive control). Nine days after treatment, OEC and GSCs/ GBM cell viability were assessed by measuring Gluc level in an aliquot of conditioned medium and intracellular Fluc activity, respectively. As expected, in each monoculture, all cells were sensitive to 5-FU, but only OCU were killed by 5-FC, proving the validity of our system (P < .001, Figure 3A) . Under the coculture conditions, 5-FC treatment did not cause any cell deaths in either GSCs or OEC (not expressing the transgene; Figure 3 , B and C); however, a statistically significant lower number of viable GSCs/GBM cells and OCU (>80%; P < .001) was observed after treatment with 5-FC when cocultured together ( Figure 3, B Figure 3D ). OCU on its own (with no 5-FC) also showed some increase in early/late apoptosis in all three GSCs confirming the viability assays above. Similarly, caspase-3/7 activity was also statistically significantly increased (P < .001) in all three GSCs cocultured with OCU when treated with 5-FC ( Figure 3E ).
OEC as a "Trojan Horse" for Glioma Gene Therapy
OECs are known to travel along with newly generated olfactory axons from the PNS neurons of the nasal mucosa to their target in the olfactory bulb in CNS. We therefore exploited the natural route of OECs to CNS to deliver CU therapeutic transgene to brain tumors. We injected MGG8 patient-derived GSCs expressing Fluc and mCherry in the striatum of nude mice brains. One week after tumor implantation, mice were divided into two groups (n ¼ 9/group) receiving a single intranasal administration of OCU or PBS (control). One week later, both groups of mice were treated with daily intraperitoneal injection of 5-FC (500 mg/kg) for 7 days. Bioluminescence imaging revealed that mice treated with a single injection of OCU and in combination with 5-FC had a statistically significant reduction of tumor growth compared with the control group treated with 5-FC alone; at day 28, mean (SD) Fluc activity was 1.08E þ 08 (9.7E þ 07) as compared with 4.1E þ 08 (2.3E þ 08), respectively (P < .001; Figure 4, A and B) . Ex vivo histological analysis for mCherry expression in the tumor as well as hemotoxylin and eosin and cleaved caspase-3 staining confirmed these results and showed that the OCUþ5-FC group had a smaller tumor size at the injection site and less invasion/migration throughout the brain, along with increased apoptosis (Figure 4, C and D) . Importantly, survival analysis showed that a single injection of OCU and treatment with 5-FC led to a statistically significant increase in the median survival of the mice (41 days for OCU þ 5-FC vs 34 days for control, ratio ¼ 0.8293, 95% confidence interval ¼ 0.4323 to 1.226, P < .001, Figure 4E ). Taken together, our results indicate that upon intranasal delivery, OCU migrate their natural route toward glioblastomas in a specific manner, and can convert prodrug 5-FC into an active 5-FU drug at the tumor site, leading to an efficient therapeutic bystander effect.
Discussion
The unique ability of the mammalian olfactory epithelium to continuously replace its olfactory receptor neurons by physiological turnover and following injury throughout life has been attributed to the olfactory ensheathing cells, a glial cell type that closely accompanies the axons as they grow from the olfactory epithelium into the olfactory bulb (3, 4) . OECs share properties with astrocytes and Schwann cells (25) and are distributed in both the PNS and CNS, which distinguishes them from typical glia (26) . OEC migration from PNS to CNS is critical for the development of the olfactory system and axonal extension after injury in neural regeneration. OECs migrate into the injury site and enhance the axon growth because of the permissive OEC environment (27) . In stroke, OECs reverses the neurological deficit, protecting the white matter from ischemic injury and improving neurological function (28) . OECs combined with olfactory nerve fibroblasts overcome the inhibitory fibrotic scar, increasing the regeneration of the lesioned nigrostriatal dopaminergic neurons in models of Parkinson's disease (29) . OECs remyelinate axons after spinal cord lesion (30) (31) (32) (33) , and induce a less severe host astrocyte response after implantation, downregulating inflammation (34) (35) (36) . The promising results obtained with OEC transplantation in animal models led to investigating their therapeutic potential in the clinic for different pathologies, including chronic spinal cord injury and amyotrophic lateral sclerosis (7-10), but they were never studied in the context of cancer. Here, we took advantage of these characteristics and, for the first time, evaluated OEC tropism to brain tumors and their potential use as a Trojan horse" to deliver therapeutic transgenes upon intranasal delivery, the OECs natural route to CNS. We showed that OECs navigate the nasal pathway to the primary glioma site and infiltrative GBM stemlike cells and deliver CU therapeutic protein, which could convert the prodrug 5-FC into an active agent 5-FU leading to a strong on-site bystander killing of glioblastomas, even with a single intranasal administration.
Because of their tropism to the tumor site, different stem cell types, including mesenchymal, neural, and embryonic, have been used as a vehicle to deliver therapeutics to gliomas (37) . Although these cells have shown some promise, several challenges persist with respect to their isolation and use. For instance, neural stem cells could potentially be harvested from the adult brain, but this process is complicated and time consuming. As an alternative, most studies use stable cell lines of immortalized neural stem cells obtained from embryonic cells, which often makes their use controversial, similar to embryonic stem cells, because of ethical, regulatory, and political concerns. Mesenchymal stem cells are obtained from bone marrow, adipose tissue, peripheral blood, umbilical cord blood, or the placenta; however, as in the case with neural stem cells, local immunosuppression can be observed upon implantation (38) . Further, spontaneous tumor formation in long-standing mesenchymal stem cell cultures has been reported, and, after implantation, a small fraction of immortalized neural stem cells continue to proliferate (39) (40) (41) . Aside from malignant transformation of stem cells, the secretion of growth factors and chemokines, and the direct local immunosuppressive effect of stem cells, may modify the tumor microenvironment such that it promotes tumor growth/metastasis (42) (43) (44) (45) . OECs, on the other hand, can be easily obtained from the olfactory epithelium, a simple procedure typically done for patients with spinal cord injury allowing autologous transplantation, overcoming both ethical issues and host graft rejection (46, 47) . Further, the unique properties of OECs, including tissue repair by affecting structural remodeling and support, modulation of the immune system, and clearance of toxic macromolecules, make them an excellent candidate as a delivery vehicle for brain tumor gene therapy. Note that no toxic or tumorigenic potential with OEC transplantation has been reported to date (9, 48) .
The intranasal pathway has been proposed as a noninvasive alternative route to deliver therapeutics to the brain. This route will bypass the blood-brain barrier, one of the major concerns in delivering any therapeutic to the CNS, and limit systemic side effects. Upon presentation at the nasal cavity, pharmacological agents reach the brain via the olfactory and trigeminal nerves (49, 50) . Nose-to-brain transport is not exclusively reserved for small molecules and viruses. NSCs and progenitor cells as well as MSCs were shown to target the tumor environment upon intranasal administration in mice bearing brain (and other types) tumors (51) (52) (53) (54) (55) . In this context, OECs have an advantage over these cells for intranasal delivery, the natural route of OEC from PNS to CNS during olfactory neuron receptor turnover, as well as autologous transplantation, lack of tumorigenicity, restorative potential, and inherent pathotropism toward inflammatory cues.
Aside from their use as a Trojan horse, OECs share several interesting properties that could be an advantage in the context of cancer in general and gliomas in particular. For instance, OECs carry immunomodulatory properties (9, 56) , are able to phagocytose cellular debris and bacteria (5,57,58), and promote neuroprotection in different CNS disease models (59, 60) . Our inculture experiments showed that OECs on their own inhibited GSCs/GBM cells proliferation, potentially having an intrinsic anticancer effect. Recently, the brain-derived neurotrophic factor (BDNF) (61, 62) , and low-dose curcumin (63) , as well as TNFa (64) , have been shown to enhance OEC migration to the injury site. Our data revealed that OEC migration decreased upon inhibition of TNFa secretion in glioma cultures, supporting the role of this cytokine in OEC tropism to GBM. It would be interesting to evaluate these OEC properties, together with one of these factors, in our GBM models and their potential use for adjuvant therapy, in combination with radiation and/ or temozolomide. Some limitations of this study should be highlighted, including the choice of the CU transgene, which also kills the OEC upon production of 5-FU at the tumor site. Because our inculture studies showed that OECs on their own inhibited tumor cell proliferation, it would be worthwhile to use a therapeutic transgene that induces tumor cell killing, but not OEC, which might lead to a more efficient therapy. An example could be soluble TRAIL (tumor necrosis factor apoptosis-inducing ligand), which can be secreted by OEC to bind to death receptors specifically on tumor cells, similar to our published work with neural stem cells (65) . Furthermore, the intranasal delivery route could also be limited to the treatment of brain/CNS tumors; however, systemic injection might be more useful for the treatment of other types of cancers.
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